PD-L1 CAR-T cells
HER2 Positive Malignancies
Sichuan UniversityEarly Phase 1Active
C
39/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 24/ 100
- Competitive Position
- 95/ 100
Competitive context
1 Active assets in the HER2 Positive Malignancies cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Dual-Targeting Her2 And Pd-L1 Car-T Cells Sichuan University | Early Phase 1 | C |
Same molecule, other indications
PD-L1 CAR-T cells is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →